- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
- 20-F Annual report (foreign)
- 2.1 Description of Share Capital
- 4.3 Purple Biotech LTD. 2016 Equity-based Incentive Plan, As Amended
- 4.29 First Amendment to Product Manufacturing Agreement, Effective As of May 17, 2020, by and Between Purple Biotech LTD. and Dexcel LTD
- 12.1 Certification
- 12.2 Certification
- 13.1 Certification
- 13.2 Certification
- 15.1 Consent of Somekh Chaikin, Independent Registered Public Accounting Firm, a Member Firm of KPMG International
- Download Excel data file
- View Excel data file
Exhibit 15.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Purple Biotech Ltd.
We consent to the incorporation by reference in registration statements No. 333-226195, No. 333-233795, No. 333-235327, No. 333-238229, and No. 333-239807 on Form F-3, registration statements No. 333-233793 and No. 333-235729 on Form F-1, and registration statements No. 333-211478, No. 333-218538, No. 333-230584 and No. 333-238481 on Form S-8. of Purple Biotech Ltd. of our report dated March 15, 2021, with respect to the consolidated statements of financial position of Purple Biotech Ltd. and its subsidiaries as of December 31, 2020 and 2019, the related consolidated statements of operations and other comprehensive loss, changes in equity and cash flows for each of the years in the three-year period ended December 31, 2020, and the related notes, and the effectiveness of internal control over financial reporting as of December 31, 2020, which report appears in the December 31, 2020 annual report on Form 20-F of Purple Biotech Ltd.
Our report refers to a change to the method of accounting for leases.
Somekh Chaikin
Member firm of KPMG International
Tel Aviv, Israel
March 15, 2021